^
    Back
    Association details:
    Biomarker:PD-L1 overexpression + TMB-H + ARID1A F2141fs*59
    Cancer:Lung Adenocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Clin Lung Cancer
    Title:

    Dramatic response to pembrolizumab monotherapy in a patient with ARID1A-mutant lung adenocarcinoma: case report

    Published date:
    01/26/2021
    Excerpt:
    Given the high PD-L1 expression, elevated TMB, and ARID1A mutation, the patient started on first-line treatment with pembrolizumab monotherapy, and, five months after initiating treatment, presented an expressive reduction of lung lesion and a complete response of the adrenal gland.
    DOI:
    https://doi.org/10.1016/j.cllc.2021.01.011